Ifosfamide in malignant mesothelioma: A phase II study

Lung Cancer

Volumn 24, Issue 1, 1999, Pages 39-43

  Andersen, Mette Klarskov ^a   Krarup Hansen, Anders ^a   Mårtensson, Gunnar ^b   Winther Nielsen, Henrik ^a   Thylen, Anders ^b   Damgaard, Karen ^a   Olling, Sante ^b   Wallin, Jan ^b  

^a Rigshospitalet   (Denmark)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

High dose ifosfamide; Malignant mesothelioma; Phase II study

Indexed keywords

ANTIBIOTIC AGENT; ASBESTOS; IFOSFAMIDE; MESNA;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DRUG EFFICACY; FEMALE; HALLUCINATION; HEMATURIA; HICCUP; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MALIGNANT MESOTHELIOMA; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; IFOSFAMIDE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SURVIVAL RATE;

EID: 0032972768     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00030-6     Document Type: Article

References (20)

1. Mårtensson G., Hagmar B., Zettergren L. Diagnosis and prognosis in malignant mesothelioma: a prospective study. Eur J Respir Dis. 65:1984;169-178.
2. Sugarbaker D.J., Norberto J.J., Bueno R. Current therapy for masothelioma. Cancer Control. 4:1997;326-334.
3. Sugarbaker D.J., Jaklitsch M.T., Liptay M.J. Mesothelioma and radical multimodality therapy: who benefits? Chest. 107:1995;345S-350.
4. Bretti S., Berutti A., Dogliotti L., Castagneto B., Bertulli R., Spadaro P. et al. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori. 84:1998;558-561.
5. Krarup-Hansen A., Hansen H.H. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol. 28:1991;319-330.
6. Krarup-Hansen A. Phase II trials of malignant mesothelioma: a commentary and update. Lung Cancer. 11:1994;305-308.
7. Maksymiuk A.W., Marschke R.F. Jr, Tazelaar H.D., Grill J., Nair S., Marks R.S. et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol. 21:1998;610-613.
8. Pennucci M.C., Ardizzoni A., Pronzato P., Fioretti M., Lanfranco C., Verna A. Combined cisplatin, doxorubicin and mitomycin for the treatment of advanced pleural mesothelioma. Cancer. 79:1997;1897-1902.
9. Samuels B.L., Herndon J.E. II, Harmon D.C., Carey R., Aisner J., Corson J.M. et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer. 82:1998;1578-1584.
10. Van Meerbeeck J., Debruyne C., Van Zandwijk N., Postmus P.E., Pennucci M.C., van Breukelen F. et al. Paclitaxel for malignant mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer. 74:1996;961-963.
11. Vogelzang N.J., Herndorn J.E., Cirrincione C., Harmon D.C., Antman K.H., Corson J.M. et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer. 79:1997;2237-2242.
12. Dirix L.Y., van Meerbeck J., Schrijvers D., Corthouts B., Prove A., van Marck E. et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol. 5:1994;653-655.
13. Falkson G., Hunt M., Borden E.C., Hayes J.A., Falkson C.I., Smith T.J. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs. 10:1992;337-343.
14. Icli F., Karaoguz H., Hasturk S., Kurt B., Akbulut H., Dincol D. et al. Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer. 15:1996;207-213.
15. Zidar B.L., Metch B., Balcerzak S.P., Pierce H.I., Militello L., Keppen M.D. et al. A phase II evaluation of ifosfamide in unresectable diffuse malignant mesothelioma. Cancer. 70:1992;2547-2551.
16. Bruhl P., Gunther U., Hoefer-Janker H., Huls W., Scheefs W., Vahlensieck W. Results obtained with fractioned ifosfamide massive-dose treatment in generalized malignant tumours. Int J Clin Pharmacol. 14:1976;29-39.
17. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: WHO, Offset publication no 48, 1979.
18. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
19. Lee Y.J., Wesley R.A. Statistical contributions to phase II trials in cancer: interpretation analysis and design. Sem Oncol. 3:1981;403-416.
20. Solheim Ø.P., Sæter G., Finnanger A.M., Stenwig A.E. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer. 65:1992;956-960.